Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 1, 2012, Pages 147-154

  Olgiati, Paolo ^a   Bajo, Emanuele ^a   Bigelli, Marco ^a   De Ronchi, Diana ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressants; Cost benefit; Depression; Pharmacoeconomics; Pharmacogenetics

Indexed keywords

AMFEBUTAMONE; CITALOPRAM;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC ASPECT; EUROPE; FEMALE; GENOTYPE; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE FACILITY; HUMAN; MAJOR DEPRESSION; MALE; PHARMACOGENETICS; PROBABILITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SOCIOECONOMICS;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; EUROPE; FEMALE; HUMANS; INCOME; MALE; MIDDLE AGED; PHARMACOGENETICS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82555190925     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.08.013     Document Type: Article

References (78)

1. Adler D.A., McLaughlin T.J., Rogers W.H., Chang H., Lapitsky L., Lerner D. Job performance deficits due to depression. Am J Psychiatry 2006, 163:1569-1576.
2. Airoldi M., Morton A. Adjusting life for quality or disability: stylistic difference or substantial dispute?. Health Econ 2009, 18:1237-1247.
3. American Psychiatric Association (APA) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000, 157:1-45.
4. Auffarth I., Busse R., Dietrich D., Emrich H. Length of psychiatric inpatient stay: comparison of mental health care outlining a case-mix from a hospital in Germany and United States of America. Ger J Psychiatry 2008, 11:40-44.
5. Aydemir O., Ergun H., Soygur H., Kesebir S., Tulunay C. Quality of life in major depressive disorder: a cross-sectional study. Turk Psikiyatri Derg 2009, 20:205-212.
6. Banks S., Pandiani G., Gauvin L., Reardon M., Schacht L., Zovistowski A. Practice patterns and hospitalization rates. Adm Policy Ment Health 1998, 26:33-44.
7. Barbui C., Hotopf M., Freemantle N., Boynton J., Churchill L., Eccles M.P., et al. WITHDRAWN: treatment discontinuation with selective serotonin reuptake inhibitors (SSRI) versus tricyclic antidepressants (TCAs). Cochrane Database Syst Rev 2007, (CD002791). Jul 18.
8. Bauer M., Monz B.U., Montejo A.L., Quail D., Dantchev N., Demyttenaere K., et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 2008, 23:66-73.
9. Bender A., Farvolden P. Depression and the workplace: a progress report. Curr Psychiatry Rep 2008, 10:73-79.
10. Bradvik L., Mattisson C., Bogren M., Nettelbladt P. Long-term suicide risk of depression in the Lundby cohort 1947-1997-severity and gender. Acta Psychiatr Scand 2008, 117:185-191.
11. Buist-Bouwman M.A., De Graaf R., Vollebergh W.A., Alonso J., Bruffaerts R., Ormel J. Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries. Acta Psychiatr Scand 2006, 113:492-500.
12. Cavalli-Sforza L.L., Piazza A. Human genomic diversity in Europe: a summary of recent research and prospects for the future. Eur J Hum Genet 1993, 1:3-18.
13. Chisholm D., Sanderson K., Ayuso-Mateos J.L., Saxena S. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004, 184:393-403.
14. Cipriani A., Geddes J.R., Furukawa T.A., Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry 2007, 52:553-562.
15. Cipriani A., Barbui C., Butler R., Hatcher S., Geddes J. Depression in adults: drug and pysical treatments. Clin Evid (online) 2011, 1: pii 1003.
16. Cuffel B.J., Azocar F., Tomlin M., Greenfield S.F., Busch A.B., Croghan T.W. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J Clin Psychiatry 2003, 64:397-402.
17. de Girolamo G., Alonso J., Vilagut G. The ESEMeD-WMH project: strenghtening epidemiological research in Europe through the study of variation in prevalence estimates. Epidemiol Psichiatr Soc 2006, 15:167-173.
18. Debonnel G., Saint-André E., Hébert C., de Montigny C., Lavoie N., Blier P. Differential physiological effects of a low dose and a high dose of venlafaxine in major depression. Int J Neuropsychopharmacol 2007, 10:51-61.
19. Fenwick E., Biford S. A guide to cost-effectiveness acceptability curve. Br J Psychiatry 2005, 187:106-108.
20. Ferrier I.N. Treatment of major depression: is improvement enough?. J Clin Psychiatry 1999, 60(Suppl 6):10-14.
21. Francois O., Currat M., Ray N., Han E., Excoffier L., Novembre J. Principal component analysis under population genetic models of range expansion and admixture. Mol Biol Evol 2010, 27:1257-1268.
22. Garriock H.A., Kraft J.B., Shyn S.I., Peters E.J., Yokoyama J.S., Jenkins G.D., et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010, 67:133-138.
23. Gartlehner G., Gaynes B.N., Hansen R.A., Thieda P., Deveaugh-Geiss A., Krebs E.E., et al. Comparative benfits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008, 149:734-750.
24. Gartlehner G., Thieda P., Hansen R.A., Gaynes B.N., Deveaugh-Geiss A., Krebs E.E., et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008, 31:851-865.
25. Gater R., Jordanova V., Maric N., Alikaj V., Bajs M., Cavic T., et al. Pathways to psychiatric care in Eastern Europe. Br J Psychiatry 2005, 186:529-535.
26. Grassi L., Rossi A., Barraco A. Factors Influencing Depression Endpoints Research (FINDER): baseline results of Italian patients with depression. Ann Gen Psychiatry 2009, 8:14.
27. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006, 78:815-826.
28. Hu X.Z., Rush A.J., Charney D., Wilson A.F., Sorant A.J., Papanicolaou G.J., et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007, 64:783-792.
29. Huezo-Diaz P., Uher R., Smith R., Rietschel M., Henigsberg N., Marusic A., et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009, 195:30-38.
30. Kang R.H., Wong M.L., Choj M.J., Paik J.W., Lee M.S. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1317-1321.
31. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010, 15:473-500.
32. Kato M., Ikenaga Y., Wakeno M., Okugawa G., Nobuhara K., Fukuda T., et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005, 20:151-156.
33. Keers P., Uher R., Huezo-Diaz P., Smith R., Jaffee S., Rietschel M., et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 2011, 2:138-145.
34. Kim H., Lim S.W., Kim S., Kim J.W., Chang Y.H., Carroll B.J., et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006, 296:1609-1618.
35. Laje G., Perlis R.H., Rush A.J., McMahon F.J. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv 2009, 60:1446-1457.
36. Lee S.H., Choi T.K., Lee E., Seok J.H., Lee S.H., Lee H.S., et al. Serotonin treatment polymorphism associated with short-temp treatment response to venlafaxine. Neuropsychobiology 2010, 62:198-206.
37. Leelahanai T. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder. J Med Assoc Thai 2010, 93(suppl 6):35-42.
38. Lin E., Chen P.S., Chang H.H., Gean P.W., Tsai H.C., Yang Y.K., et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1167-1172.
39. Llorca P.M., Fernandez J.L. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007, 61:702-710.
40. Milea V., Verpillat P., Guelfucci F., Toumi M., Lamure M. Prescription patterns of antidepressant: findings from a US claims database. Curr Med Res Opin 2010, 26:1343-1353.
41. Min W., Li T., Ma X., Li Z., Yu T., Gao D., et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology 2009, 205:409-417.
42. Moller H.J. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand Suppl 2003, 73-80.
43. Mrazek D.A., Rush A.J., Biernacka J.M., O'Kane D.J., Cunningham J.M., Wieben E.D., et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:341-351.
44. Nelis M., Esko T., Magi R., Zimprich F., Zimprich A., Toncheva D., et al. Genetic structure of Europeans: a view from the North-East. PLoS One 2009, 4:e5472.
45. OECD. OECD Health Data 2009. ww.ecosante.org; 2009.
46. Papakostas G.I., Trivedi M.H., Alpert J.E., Seifert C.A., Krishen A., Goodale E.P., et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 2008, 42:134-140.
47. Perlis R.H., Patrick A., Smoller J.W., Wang P.S. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 2009, 34:2227-2236.
48. Pollock B.G., Ferrell R.E., Mulsant B.H., Mazumdar S., Miller M., Sweet R.A., et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000, 23:587-590.
49. Popp J., Leucht S., Heres S., Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy-a pilot study. Pharmacogenomics 2006, 7:159-166.
50. Posternak M.A., Zimmerman M. How accurate are patients in reporting their antidepressant treatment history?. J Affect Disord 2003, 75:115-124.
51. Revicki D., Wood M. Patient-assigned health state utilities for depression related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998, 48:25-36.
52. Rush A., Trivedi M., Wisniewski S., Nierenberg A., Stewart J., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
53. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231-1242.
54. Rytsala H.J., Melartin T.K., Leskela U.S., Sokero T.P., Lestela-Mielonen P.S., Isometsa E.T. Functional and work disability in major depressive disorder. J Nerv Ment Dis 2005, 193:189-195.
55. Sapin C., Fantino B., Nowicki M.L., Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004, 2:20.
56. Sarnes M.W., Frankum L.E. Pharmacoeconomic evaluation of antidepressant therapies. Manag Care 2004, 13:34-41.
57. Serretti A., Cusin C., Rossini D., Artioli P., Dotoli D., Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004, 129B:36-40.
58. Serretti A., Artioli P., Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 2005, 15:61-67.
59. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007, 12:247-257.
60. Serretti A., Olgiati P., Bajo E., Bigelli M., De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 2011, 12:501-515.
61. Shaw J., Zachr W. Application of probabilistic sensitivity analysis in decision analytic modeling. Pract Pharmacoeconomics 2002, 37:32-40.
62. Siskind D., Baingana F., Kim J. Cost-effectiveness of group psychotherapy for depression in Uganda. J Ment Health Policy Econ 2008, 11:127-133.
63. Smits K.M., Smits L.J., Schouten J.S., Peeters F.P., Prins M.H. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clin Ther 2007, 29:691-702.
64. Smits K.M., Smits L.J., Peeters F.P., Schouten J.S., Janssen R.G., Smeets H.J., et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008, 18:184-190.
65. Sobocki P., Jonsson B., Angst J., Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006, 9:87-98.
66. Soeteman D.I., Timman R., Trijsburg R.W., Verheul R., Busschbach J.J. Assessment of the burden of disease among inpatients in specialized units that provide psychotherapy. Psychiatr Serv 2005, 56:1153-1155.
67. Stallings S.C., Huse D., Finkelstein S.N., Crown W.H., Witt W.P., Maguire J., et al. A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics 2006, 7:853-862.
68. Sullivan P.W., Valuck R., Saseen J., MacFall H.M. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004, 18:911-932.
69. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin E., Warden D., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354:1243-1252.
70. Ustun T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., Murray C.J. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004, 184:386-392.
71. Villafuerte S.M., Vallabhaneni K., Sliwerska E., McMahon F.J., Young E.A., Burmeister M. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 2009, 19:281-291.
72. Warden D., Trivedi M.H., Wisniewski S.R., Davis L., Nierenberg A.A., Gaynes B.N., et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 2007, 164:1189-1197.
73. Watkins K.E., Burnam M.A., Orlando M., Escarce J.J., Huskamp H.A., Goldman H.H. The health value and cost of care for major depression. Value Health 2009, 12:65-72.
74. Wedlund P., de Leon J. Pharmacogenetic testing: the cost factor. Pharmacogenomics J 2001, 1:171-174.
75. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996, 276:1253-1258.
76. WHO Mental Health Atlas 2005 Geneva. http://wwww.who.int/mental_health/media.
77. Wong M.L., O'Kirwan F., Hannestad J.P., Irizarry K.J., Elashoff D., Licinio J. St. John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol Psychiatry 2004, 9:237-251.
78. Zetin M., Hoepner C.T., Bjornson L. Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull 2006, 39:38-104.